SETD1A
| | | [@mukai2019]
|---|---| [@hoshii2018]
| Full Name | SET Domain Containing 1A, Histone Lysine Methyltransferase | [@frost2014]
| Gene Symbol | SETD1A | [@kummeling2021]
| Aliases | KMT2F, SET1, SET1A | [@basavarajappa2021]
| Chromosome | 16p11.2 | [@nagahama2020]
| Gene Type | Protein-coding | [@johansson2016]
| OMIM | 611052 | [@li2016]
| UniProt | O15047 |
| HGNC | 29010 |
| Entrez Gene | 9739 |
| Ensembl | ENSG00000099381 |
SETD1A is a human gene. Variants in SETD1A have been implicated in Schizophrenia, Alzheimer's Disease, Neurodevelopmental Disorder (SETD1A-Related). This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
SETD1A (SET Domain Containing 1A), also known as KMT2F, encodes a histone H3 lysine 4 (H3K4) methyltransferase that is the catalytic subunit of the SETD1A/COMPASS complex. SETD1A deposits H3K4me3 at promoters of actively transcribed genes, a histone mark essential for transcription initiation and RNA polymerase II recruitment.[1] SETD1A is one of six mammalian H3K4 methyltransferases in the KMT2/MLL family and has emerged as one of the strongest individual gene risk factors for schizophrenia. In neurons, SETD1A regulates synaptic gene expression, axonal branching, and cortical neuron morphology. Haploinsufficiency causes a neurodevelopmental syndrome with cognitive impairment and increased risk for neuropsychiatric and neurodegenerative disorders including Alzheimer's disease.
SETD1A contains an N-terminal RNA recognition motif (RRM), a central region mediating COMPASS interactions, and a C-terminal SET domain catalyzing H3K4 methylation. The SET domain requires assembly into the COMPASS complex (with WDR5, RBBP5, ASH2L, DPY30) for catalytic activity.
The SETD1A/COMPASS complex deposits H3K4me3 at transcription start sites of actively transcribed genes. H3K4me3 is read by the TAF3 subunit of TFIID, bridging histone modifications to RNA polymerase II pre-initiation complex assembly. SETD1A is responsible for the bulk of H3K4me3 at most gene promoters in mammalian cells, distinguishing it from MLL1/2 (which target developmental/Hox gene promoters) and MLL3/4 (which target enhancers with H3K4me1).[1]
In cortical neurons, SETD1A-dependent H3K4me3 is critical for expression of synaptic genes including glutamate receptor subunits (GRIN1, GRIN2A, GRIN2B), scaffolding proteins (DLG4/PSD-95, SHANK3), and activity-dependent transcription factors (MEF2C, CREB1). SETD1A haploinsufficiency reduces H3K4me3 at these promoters by 30-50%, producing measurable decreases in synaptic protein levels and synaptic transmission efficacy.[2]
SETD1A regulates axonal branching through transcriptional control of cytoskeletal regulators. Setd1a heterozygous knockout mice exhibit reduced axonal branch complexity in cortical pyramidal neurons, decreased dendritic spine density, and deficits in cortical circuit connectivity. These morphological defects are partially rescuable by increasing H3K4me3 through pharmacological inhibition of KDM5 demethylases (KDM5B, KDM5C).[3]
SETD1A is recruited to DNA double-strand breaks where it deposits H3K4me3 to facilitate homologous recombination repair. In post-mitotic neurons that primarily use NHEJ, SETD1A's repair function intersects with KDM4C-mediated H3K9me3 removal at damage sites. SETD1A loss increases DNA damage burden, accelerating aging-related neuronal vulnerability.[4]
Recent research has revealed a critical role for SETD1A in mitochondrial dynamics and neuronal survival under oxidative stress conditions. SETD1A regulates expression of key mitochondrial fusion and fission genes including MFN1, MFN2, OPA1, and DRP1 (DNM1L). Loss of SETD1A leads to fragmented mitochondria, reduced ATP production, and increased susceptibility to oxidative damage.[14]
In neurons, SETD1A deficiency causes impaired mitophagy—the selective autophagy process that removes damaged mitochondria. SETD1A-dependent H3K4me3 at promoters of PINK1 and PARKIN (PRKN) genes is required for their expression. Given that PINK1 and PARKIN are central to mitophagy in Parkinson's disease, SETD1A decline may contribute to the accumulation of dysfunctional mitochondria in dopaminergic neurons.[14]
Loss-of-function variants in SETD1A are among the strongest individual gene risk factors for schizophrenia, with an odds ratio exceeding 35. Exome sequencing studies have identified protein-truncating variants in SETD1A in ~0.1% of schizophrenia cases. Affected individuals typically present with early-onset schizophrenia, cognitive impairment, and developmental delays preceding psychosis onset.[2]
Recent genome-wide association studies have identified multiple SETD1A variants associated with schizophrenia susceptibility. The rs11150601 intron variant shows significant association specifically in female patients from the UK Biobank cohort, suggesting sex-specific effects of SETD1A genetic variation on schizophrenia risk.[13]
In Alzheimer's disease, SETD1A expression declines in vulnerable brain regions, leading to loss of H3K4me3 at synaptic gene promoters. This contributes to the synaptic gene downregulation that precedes neuronal death. Additionally, reduced SETD1A activity impairs DNA repair capacity, increasing vulnerability to oxidative DNA damage driven by amyloid-beta and neuroinflammation.[5]
The interaction between SETD1A and tau pathology involves competition for chromatin access: hyperphosphorylated tau associates with H3K4me3-marked promoters and disrupts SETD1A-COMPASS chromatin occupancy, amplifying H3K4me3 loss at synaptic genes.[5]
SETD1A interacts with multiple pathological features of Alzheimer's disease beyond chromatin relaxation. In cellular models, amyloid-beta oligomers suppress SETD1A expression and COMPASS complex formation, creating a feedforward loop where amyloid pathology impairs the epigenetic machinery needed for synaptic gene expression.[5]
SETD1A also modulates neuroinflammation through regulation of glial cell gene programs. In microglia, SETD1A controls expression of TNF, IL1B, and IL6 in response to amyloid-beta exposure. SETD1A deficiency leads to exaggerated neuroinflammatory responses, amplifying neuronal vulnerability.[14]
Heterozygous loss-of-function variants cause a recognizable neurodevelopmental syndrome (OMIM #619811) characterized by intellectual disability (typically mild-moderate), speech and language delay, behavioral features (ADHD, autism spectrum traits), and variable facial dysmorphism. Most identified variants are protein-truncating (frameshift, nonsense, splice-site) and arise de novo.[6]
SETD1A-dependent H3K4me3 at dopaminergic neuron-specific gene promoters (including TH, NURR1, PITX3) is required for maintenance of dopaminergic identity. Age-related SETD1A decline in the substantia nigra may contribute to dopaminergic neuron vulnerability in Parkinson's disease, though direct genetic associations remain under investigation.[7]
Recent population-based studies have identified epigenetic mechanisms linking environmental factors to PD risk through SETD1A. Analysis of the UK Biobank cohort revealed that educational attainment—a known protective factor against PD—correlates with SETD1A expression levels, suggesting that higher SETD1A activity may buffer against dopaminergic neurodegeneration through enhanced chromatin regulation of neuroprotective genes.[11]
SETD1A is ubiquitously expressed across all brain regions, with highest levels in the cerebral cortex, hippocampus, and thalamus. During development, SETD1A expression peaks during active neurogenesis and synaptogenesis (embryonic day 14 through postnatal day 14 in mice), then declines to moderate adult levels.[2]
At the cellular level, SETD1A is expressed in all major neural cell types but is most abundant in excitatory projection neurons. Chandelier and parvalbumin-positive (PV+) interneurons also express SETD1A, consistent with their dysfunction in SETD1A-haploinsufficient schizophrenia models. Oligodendrocyte expression of SETD1A regulates myelination gene programs.[3]
Age-related decline in SETD1A expression represents a conserved feature of brain aging across species. Transcriptomic analyses of human brain tissue show progressive reduction in SETD1A mRNA levels starting in the fifth decade of life, with the most pronounced declines in the hippocampus and prefrontal cortex. This decline correlates with reduced H3K4me3 at synaptic gene promoters and provides a mechanistic link between normal aging and increased susceptibility to neurodegenerative diseases.[14]
Mouse models with conditional Setd1a knockout in adult neurons show accelerated cognitive decline, validating SETD1A as a key regulator of age-related cognitive function. These mice exhibit synaptic protein downregulation, dendritic spine loss, and impaired long-term potentiation (LTP) even in the absence of amyloid or tau pathology, suggesting that SETD1A decline alone can drive cognitive vulnerability.[15]
| Variant | Type | Association | Reference |
|---|---|---|---|
| p.R913* | Nonsense | Schizophrenia, intellectual disability | [2] |
| p.G535Afs*12 | Frameshift | Early-onset schizophrenia | [2] |
| c.4582-2A>G | Splice-site | NDD with speech delay | [6] |
| 16p11.2 microdeletion | CNV | ASD, developmental delay (includes SETD1A) | [6] |
| rs3782089 | Promoter SNP | Cognitive performance in general population | [8] |
| rs11150601 | Intron SNP | Female schizophrenia risk | [13] |
The SETD1A protein consists of multiple functional domains that coordinate its enzymatic activity and cellular localization. Understanding these domains provides insight into disease-causing mutations and therapeutic targeting opportunities.
SETD1A contains several distinct domains: an N-terminal RNA recognition motif (RRM) that mediates interactions with nascent transcripts and facilitates promoter targeting; a central region containing multiple PHD fingers that recognize unmodified histone H3 tails and contribute to target gene specificity; and the C-terminal SET domain that catalyzes H3K4 methylation. The SET domain requires assembly into the larger COMPASS (Complex of Proteins Associated with Set1) complex for full catalytic activity.[1]
The COMPASS core consists of WDR5 (WD repeat-containing protein 5), RBBP5 (Retinoblastoma-binding protein 5), ASH2L (Absent, Small, Or Homeotic 2-like), and DPY30. WDR5 binds directly to SETD1A through a conserved "WDR5 interaction" (WDI) motif, bridging SETD1A to the rest of the complex. Crystal structures have revealed that the SET domain adopts an auto-inhibited conformation in the absence of COMPASS assembly, with the active site blocked by an N-SET loop. COMPASS binding relieves this inhibition, positioning the substrate H3 tail for methylation.[10]
Over 200 pathogenic variants in SETD1A have been identified in individuals with neurodevelopmental disorders. These variants are enriched in the SET domain (affecting catalytic function) and the WDI motif (impairing COMPASS assembly). Functional studies show that most pathogenic variants reduce H3K4me3 activity by >80%, consistent with haploinsufficiency as the disease mechanism.[2]
Common pathogenic variants include: p.R913* (nonsense, truncates SET domain), p.G535Afs*12 (frameshift, destabilizes protein), and splice-site variants that cause exon skipping. Missense variants in the SET domain (e.g., p.R1280W, p.L1300F) typically show partial loss of function (30-70% reduction) and may present with milder phenotypes.[6]
The SETD1A/COMPASS complex represents the major H3K4me3-writing machinery in mammalian cells, and its regulation is tightly coupled to cellular metabolism, signaling, and stress responses.
SETD1A/COMPASS functions as a co-activator for RNA polymerase II transcription by depositing H3K4me3 at promoter nucleosomes. This mark is read by multiple effector proteins, including TAF3 (TBP-associated factor 3) in the TFIID complex, which directly binds H3K4me3 through its PHD finger. This interaction stabilizes TFIID at promoters and promotes PIC (pre-initiation complex) assembly.[1]
Beyond TFIID, SETD1A-generated H3K4me3 recruits additional co-activators, including the histone acetyltransferases p300/CBP, which acetylate histone H3 and H4 to further open chromatin. This feedforward mechanism ensures robust transcriptional activation of SETD1A target genes, particularly those involved in synaptic function and neuronal survival.[1]
SETD1A/COMPASS activity is modulated by multiple signaling pathways. Phosphorylation of SETD1A by CK2 enhances COMPASS stability and H3K4me3 activity. In contrast, stress-activated kinases such as JNK and p38 can phosphorylate SETD1A to reduce its chromatin binding, providing a mechanism for stress-induced transcriptional repression.[14]
The availability of S-adenosylmethionine (SAM)—the methyl donor for H3K4 methylation—links COMPASS activity to cellular metabolism. Under conditions of reduced SAM (e.g., mitochondrial dysfunction, oxidative stress), SETD1A activity decreases, contributing to the epigenetic changes observed in neurodegeneration.[15]
SETD1A haploinsufficiency provides a clear therapeutic rationale: restoring H3K4me3 levels at target promoters could ameliorate cognitive deficits in SETD1A-related disorders and potentially in AD. Two main approaches are being investigated:
KDM5 inhibitor therapy: Pharmacological inhibition of KDM5B/KDM5C H3K4 demethylases increases H3K4me3 levels genome-wide, partially compensating for SETD1A loss. KDM5 inhibitors (including CPI-455 and KDM5-C70) have shown cognitive improvement in Setd1a-haploinsufficient mouse models.[9]
SETD1A activator development: Small molecules that enhance SETD1A-COMPASS catalytic activity or stabilize the complex represent an alternative strategy. The requirement for COMPASS assembly creates opportunities for allosteric activators targeting the WDR5-SETD1A interface.[10]
Gene therapy: AAV-mediated SETD1A supplementation in neurons is being explored but faces challenges due to the large gene size (>5 kb coding sequence exceeding AAV packaging limits). Mini-gene constructs retaining the SET domain and critical COMPASS interaction regions are under development.[3]
Mitochondrial protection: Given the role of SETD1A in mitochondrial gene regulation, small molecules that enhance mitochondrial function (e.g., PINK1 activators, mitophagy inducers) may provide indirect therapeutic benefit in SETD1A-deficient states.[14]
The SETD1A gene and its COMPASS complex are evolutionarily conserved across eukaryotes, reflecting the fundamental importance of H3K4me3 in transcriptional regulation. Yeast Set1, the ancestral ortholog of SETD1A, functions as the sole H3K4 methyltransferase in Saccharomyces cerevisiae, establishing the core COMPASS architecture over 1 billion years ago. The expansion to six mammalian H3K4 methyltransferases (SETD1A, SETD1B, MLL1, MLL2, MLL3, MLL4) reflects functional specialization during vertebrate evolution.
In Drosophila melanogaster, the Set1 ortholog (dSet1) is required for homeotic gene expression and proper body plan development. Knockdown of dSet1 leads to lethal developmental defects, demonstrating the non-redundant essential function of this enzyme family. Notably, fly SETD1A orthologs show particular importance in neuronal development, with mutants displaying defects in learning and memory circuits.
Vertebrate SETD1A and SETD1B arose from a gene duplication event in the common ancestor of teleost fish and tetrapods. Functional divergence included acquisition of novel target gene specificity, with SETD1A becoming the predominant methyltransferase for synaptic genes while SETD1B assumed greater importance in mitochondrial gene regulation. This specialization is reflected in the distinct phenotypic consequences of SETD1A versus SETD1B loss in mice: Setd1a haploinsufficiency produces neurodevelopmental and cognitive deficits, while Setd1b deficiency causes embryonic lethality with cardiac and neural tube defects.
The rapid evolution of SETD1A regulatory regions in primates—including species-specific enhancer elements in the brain—suggests that SETD1A expression may have been a target of positive selection during human evolution. This hypothesis is supported by the presence of human-specific SETD1A expression patterns in the prefrontal cortex, a brain region expanded in primates.[13]
Mouse models have been instrumental in understanding SETD1A function in the nervous system and validating therapeutic approaches.
heterozygous Setd1a knockout mice (Setd1a+/-) recapitulate key features of SETD1A haploinsufficiency in humans. These mice show reduced H3K4me3 at synaptic gene promoters, decreased synaptic protein levels, impaired spatial learning and memory, and behavioral abnormalities relevant to schizophrenia (reduced prepulse inhibition, increased locomotor activity in novel environments).[3]
Conditional knockout models targeting Setd1a in adult neurons allow separation of developmental from adult-onset functions. These mice develop normally but exhibit rapid cognitive decline after Setd1a deletion, demonstrating that SETD1A is required for maintenance of cognitive function in the adult brain, not just during development.[15]
Neuron-specific Setd1a knockdown using AAV-mediated RNAi produces similar phenotypes, providing a model for acute SETD1A loss that mirrors the age-related decline observed in human brains. These models are being used to test therapeutic interventions.[9]
Multiple studies have demonstrated rescue of Setd1a haploinsufficiency phenotypes through various approaches. Pharmacological KDM5 inhibition using CPI-455 or KDM5-C70 restores H3K4me3 levels, improves synaptic protein expression, and rescues cognitive deficits in Setd1a+/- mice. Importantly, rescue is observed even when treatment begins after symptom onset, suggesting therapeutic relevance for patients with SETD1A-related disorders.[9]
Viral delivery of wild-type Setd1a using AAV vectors partially rescues phenotypes when administered during early development. However, adult administration shows limited efficacy, likely due to the large coding sequence and challenges achieving sufficient neuronal transduction.[3]